Trogarzo™ is indicated for the treatment of multidrug-resistant HIV-1 infection in heavily treatment-experienced patients.
Trogarzo (ibalizumab-uiyk) for the Treatment of Multidrug-Resistant HIV-1 Infection Read More »
Today, the U.S. Food and Drug Administration approved Trogarzo (ibalizumab-uiyk), a new type of antiretroviral medication for adult patients living with HIV who have tried multiple HIV medications in the past (heavily treatment-experienced) and whose HIV infections cannot be successfully treated with other currently available therapies (multidrug resistant HIV, or MDR HIV).
FDA approves new HIV treatment for patients who have limited treatment options Read More »
This study assessed the effect of nanoparticles (NMCAB) on the biodistribution and viral clearance profiles of current CAB LAP formulations.
Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles. Read More »
The two-drug combination of all-injectable, long-acting cabotegravir plus rilpivirine every 4 weeks or every 8 weeks was as effective as daily three-drug oral therapy at maintaining HIV-1 viral suppression through 96 weeks and was well accepted and tolerated.
The aim of this review is to summarize the biological bases, the available information on completed and ongoing clinical trials and the potential development of long-acting regimens for the treatment and prevention of HIV infection.
Ongoing studies are evaluating long-acting dosing of lenacapavir for treating HIV-1 in combination with other antiretrovirals and preventing HIV-1 as a single agent.
HIV Capsid Lenacapavir Review Treatment & Prevention, PK, Mechanism, Resistance Read More »
Modern antiretroviral therapy has demonstrated effectiveness in preexposure prophylaxis (PrEP) and treatment of HIV infection. There is a demand for prevention and treatment regimens that could overcome challenges of improving adherence, toxicity, and dosing convenience.
HPTN/IMPAACT Network Meeting 2016 Presentation
Cabotegravir as Pre-Exposure Prophylaxis for HIV Prevention Read More »
This study assesses cabotegravir plus rilpivirine, as a two-drug oral antiretroviral regimen, for the maintenance of viral suppression in antiretroviral-naive HIV-1-infected individuals.
PrEP, after approval of Truvada, continues to evolve to address adherence limitations of daily dosing. As a long-acting injectable antiretroviral drug, cabotegravir long-acting permits quarterly dosing and demonstrated high efficacy in macaque models supporting dose selection and clinical development. Clinical studies have confirmed dose selection in phase 2a trials with cabotegravir long-acting to ultimately lead
Cabotegravir long-acting for HIV-1 prevention Read More »
